Jul 28, 2022 03:03 PM

Shanghai Composite Index Rose 0.21% on Thursday

China’s benchmark Shanghai Composite Index (000001.SH) gained 0.21% on Thursday, while the Shenzhen Component Index (399001.SZ) rose 0.23%.

Shanghai’s tech-heavy STAR 50 Index (000688.SH) gained 1.19% for the day, while Shenzhen’s similar ChiNext Index (399006.SZ) fell 0.31%.

Below is a rundown of the top China business and finance stories, plus other news for the day:

· Ant Makes Fresh Move to Advance Internal Reshuffle

Alibaba-backed fintech giant sets up a new committee under the board to oversee risk management and consumer protection

· Steel Profits Plunge in June Amid Slack Demand and Rising Costs

Chinese industry’s earnings slide 93.8% from a year ago as iron ore and coking coal prices rise and housing demand continues its downward spiral

· Industrial Bank Gets a Boost as Fujian Government Expands Its Stake

Biggest state shareholder plans to buy as much as $148 million of bank’s equity to bolster the stock in support of a digital transition

· Weeks After Hong Kong Offering, Miniso Shares Tank on Short-Seller Attack

Retailer says the allegations that it's lying about its business model are ‘without merit’

· Analysis: Dutch Carmaker Stellantis and State-Owned Guangzhou Auto Go Their Own Ways

The duo is shutting down their money-losing Jeep JV, which recorded a more than 84% drop in first-half sales

· Shanghai Neighborhoods Resubmit to Lockdown as Covid Cases Rebound

Drivers and delivery personal, as well as ‘closed-loop’ quarantine staff, have been spreading Covid-19 across the city, officials say

· Opinion: AI and Open Medical Data Are the Keys to Solving Global Health Inequity

Global health disparities will improve or worsen depending on how much data researchers can access

· China Names New Disease Control Chief

Shen Hongbing, an epidemiologist and oncologist, succeeds high-profile China CDC leader Gao Fu, who is retiring

· Former Everbright Executive Under Anti-Graft Probe

Chen Shuang is being investigated for ‘serious disciplinary violations,’ according to Communist Party’s graft busters

· Analysis: How Azvudine Became China’s First Approved Homegrown Covid Pill

Little-known Genuine Biotech’s AIDS drug turns out to help Covid patients and may turn into a multibillion-dollar product

Click here to read more of the latest news.

This article was generated by Caixin Automation.

Download our app to receive breaking news alerts and read the news on the go.

Follow the Chinese markets in real time with Caixin Global’s new stock database.

Share this article
Open WeChat and scan the QR code
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription